Recent insights into the roles and therapeutic potentials of GLS1 in inflammatory diseases

Jian-Xiang Sheng1, Yan-Jun Liu1, Jing Yu1

  • 1State Key Laboratory for Quality and Safety of Agro-Products, School of Marine Sciences, Ningbo University, Ningbo, Zhejiang, 315211, China.

PubMed

Insights

Glutaminase 1 (GLS1) is vital for inflammation by controlling glutaminolysis. Inhibiting GLS1 can reduce inflammation, offering new therapeutic strategies for inflammatory diseases.

Area of Science:

  • Biochemistry
  • Immunology
  • Metabolic Pathways

Background:

  • Glutaminase 1 (GLS1) is the rate-limiting enzyme in glutaminolysis, a metabolic process impacting biological functions.
  • While GLS1's role in cancer is established, its connection to inflammation requires deeper investigation.

Purpose of the Study:

  • To comprehensively review GLS1's structure, function, and role in inflammatory pathways.
  • To summarize evidence linking GLS1 to inflammatory diseases and explore therapeutic potential of GLS1 inhibitors.

Main Methods:

  • Literature review of GLS1's involvement in inflammation.
  • Analysis of GLS1's regulatory role in mediating glutaminolysis.
  • Exploration of GLS1 inhibitors as anti-inflammatory agents.

Main Results:

  • GLS1 critically regulates inflammation by mediating glutaminolysis.
  • Targeting GLS1 with inhibitors effectively alleviates GLS1-induced inflammation.
  • Evidence supports GLS1's involvement in various inflammatory diseases.

Conclusions:

  • GLS1 is a key regulator of inflammation via glutaminolysis.
  • GLS1 inhibitors present a promising therapeutic avenue for inflammatory conditions.
  • Further research is needed to overcome challenges in GLS1 functional exploration and inhibitor development.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
816
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
437
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
439
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.2K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
405
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.1K